Chun-Guang, W., Jun-Qing, Y., Bei-Zhong, L., Dan-Ting, J., Chong, W., Liang, Z., et al. (2010) Anti-Tumor Activity of Emodin against Human Chronic Myelocyticleukemia K562 Cell Lines in Vitro and in Vivo. European Journal of Pharmacology, 627, 33-41.
https://doi.org/10.1016/j.ejphar.2009.10.035

has been cited by the following article:

• TITLE: Molecular Docking and ADMET Study of Emodin Derivatives as Anticancer Inhibitors of NAT2, COX2 and TOP1 Enzymes

  AUTHORS: Daniel M. Shadrack, Valence M. K. Ndesendo

  KEYWORDS: Human Arylamine N-Acetyltransferase 2 (NAT2), Cyclooxygenase 2 (COX2), Topoisomerase 1 (TOP1), Emodin, In Silico Inhibition, Pharmacokinetics, Molecular Docking

  JOURNAL NAME: Computational Molecular Bioscience, Vol.7 No.1, March 16, 2017

  ABSTRACT: Over the past years natural products and/or their derivatives have continued to provide cancer chemotherapeutics. Glycosides derivatives of emodin are known to possess anticancer activities. An in silico study was carried out to evaluate emodin derivatives as inhibitors of Arylamine N-Acetyltransferase 2, Cyclooxygenase 2 and Topoisomerase 1 enzymes, predict their pharmacokinetics and explore their bonding modes. Molecular docking study suggested that D2, D5, D6 and D9 to be potent inhibitors of NAT2, while D8 was suggested to be a potent inhibitor of TOP1. Derivatives D2, D5, D6 and D9 bind to the same pocket with different binding conformation. Pharmacokinetic study suggested that selected emodin derivatives can be potential cancer chemotherapeutic agent. Physicochemical parameters such density, balaban index, surface tension, logP and molar reflectance correlated to compounds activity. These finding provides a potential strategy towards developing NAT2 and TOP1 inhibitors.